Antibodies News and Research

RSS

UTMB researchers improve existing experimental vaccine for Rift Valley fever virus

University of Texas Medical Branch researchers have significantly improved an existing experimental vaccine for Rift Valley fever virus, making possible the development of a more effective defense against the dangerous mosquito-borne pathogen.

28 Jun 2012

Vaccine for nicotine addiction developed

Researchers at Weill Cornell Medical College have developed and successfully tested in mice an innovative vaccine to treat nicotine addiction.

28 Jun 2012

GSD receives FDA clearance for next-generation Lyme disease Line Immunoassay

Gold Standard Diagnostics (GSD) today announced FDA clearance of its next-generation Lyme disease Line Immunoassay which offers excellent specificity and sensitivity at any disease stage.

28 Jun 2012

FDA approves test for dengue virus infection

The first test that can detect the presence of the dengue virus itself rather than antibodies to the virus has been approved for use by the US Food and Drug Administration.

27 Jun 2012

Second potential immune checkpoint target for cancer immunotherapy announced by Compugen

Compugen Ltd. (NASDAQ: CGEN) announced today results demonstrating the therapeutic potential of CGEN-15022, a Compugen-discovered B7/CD28-like membrane protein, as an immune checkpoint target for treatment of multiple cancers.

27 Jun 2012

Having antibodies for cutaneous HPV and sun exposure can act synergistically in BCC, SCC

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida and the German Cancer Research Center in Heidelberg have found that having antibodies for cutaneous types of human papillomavirus (HPV), coupled with sun exposure (ultraviolet radiation) or poor tanning ability, can act "synergistically" in the development of non-melanoma skin cancers such as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).

26 Jun 2012

Merck Serono, Compugen announce establishment of Neviah Genomics

Merck Serono, a division of Merck, Darmstadt, Germany, and Compugen Ltd. today announced the establishment of Neviah Genomics, a novel start-up company focused on the discovery and development of novel biomarkers for the prediction of drug-induced toxicity.

26 Jun 2012

DVS Sciences announces business agreement with Cytobank

DVS Sciences, Inc., a privately held innovator and manufacturer of novel CyTOF multi-parameter single-cell analyzers and reagents for biological research, today announced a business agreement with Cytobank, Inc., a privately held developer of cloud based scientific, informatics and software solutions for the flow cytometry market.

25 Jun 2012

Scientists recommend new type of therapeutic approach to dementia

Scientists at Charité - Universitätsmedizin Berlin have succeeded in recommending a new type of therapeutic approach to dementia. The study published in the journal Neurology shows that immune reactions against the body's own nerve cells can be the cause of advanced dementia and an appropriate immune suppressive therapy can develop with significant effectiveness.

23 Jun 2012

AbGenomics raises $11 million in current financing round

AbGenomics International announced today that it has raised $11 million in current financing round. It brings total investment in AbGenomics to approximately $52 million since its inception in 2000.

23 Jun 2012

Patients taking common blood pressure drug show symptoms of celiac disease

Mayo Clinic researchers have discovered an association between a commonly prescribed blood pressure drug, Olmesartan, and severe gastrointestinal issues such as nausea, vomiting, diarrhea, weight loss and electrolyte abnormalities -- symptoms common among those who have celiac disease. The findings are published online today in the medical journal Mayo Clinic Proceedings.

22 Jun 2012

Link between Olmesartan drug and severe GI issues

22 Jun 2012

GBM patients with CNP subtype may have less aggressive subtype of cancer

A diagnosis of glioblastoma multiforme (GBM) is generally a death sentence, but new research from the University of Wisconsin-Madison lab of Dr. John Kuo shows that at least one subtype is associated with a longer life expectancy. This discovery could help with better patient prognoses and lead to targeted drug treatments for GBM subtypes.

21 Jun 2012

FDA approves CDC DENV-1-4 Real Time RT PCR Assay to treat dengue

The Centers for Disease Control and Prevention has developed a new diagnostic test to detect the presence of dengue virus in people with symptoms of dengue fever or dengue hemorrhagic fever. The test, called the CDC DENV-1-4 Real Time RT PCR Assay, has been authorized by the Food and Drug Administration for use in the United States and can be performed using equipment and supplies many public health laboratories already use to diagnose influenza.

21 Jun 2012

Childhood viral CNS infections increase psychosis risk

Viral infections of the central nervous system in childhood are associated with nearly a two-fold increased risk for non-affective psychosis and schizophrenia in adulthood, a review and meta-analysis of published studies shows.

20 Jun 2012

Antimicrobial exposure may increase risk of allergies in children

Exposure to common antibacterial chemicals and preservatives found in soap, toothpaste, mouthwash and other personal-care products may make children more prone to a wide range of food and environmental allergies, according to new research from Johns Hopkins Children's Center.

20 Jun 2012

NCOA spearheads new initiative to help protect older adults from influenza

The National Council on Aging announced today it is spearheading a new initiative to help protect older adults from influenza this upcoming flu season. The educational program, Flu + You, in collaboration with Sanofi Pasteur, aims to educate older adults and their caregivers about the seriousness of influenza, the importance of annual influenza immunization, and available vaccine options.

20 Jun 2012

DSM XD high cell density process technology granted patents in several countries

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM N.V., announced today that several countries have granted patents or have given statements of patent allowance to its proprietary XD® high cell density process technology.

19 Jun 2012

SDIX advanced Genomic Antibody Technology to be highlighted at BIO International Convention

SDIX today announced that it will be showcasing progress with its advanced Genomic Antibody Technology data package this week's BIO International Convention, one of the largest global partnering events for the biotechnology industry.

19 Jun 2012

Allergy risk in children linked to antibacterials in personal-care products

Exposure to common antibacterial chemicals found in soap, toothpaste, mouthwash and other personal-care products may make children more prone to a wide range of food and environmental allergies, according to new research from Johns Hopkins Children’s Center.

19 Jun 2012